Elutia (ELUT) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Mission and product overview

• Focus on humanizing medicine by combining pharmaceuticals with biologics to create drug-eluting biologic products.

• Commercial-stage company with $27 million revenue run rate, driven by EluPro and SimpliDerm product lines.

• EluPro is the first antibiotic-eluting bioenvelope, targeting the $600 million pacemaker and defibrillator market.

• SimpliDerm is positioned in the breast reconstruction space and is also growing.

Market opportunity and competitive landscape

• 550,000–600,000 pacemaker and defibrillator procedures annually in the US, with a 5%-7% complication rate due to foreign body response.

• Only four major players in the US market; Medtronic dominates with 40% share and owns TYRX, a synthetic antibiotic-eluting envelope.

• TYRX generates $250–$300 million annually but is only available to Medtronic devices, leaving 60% of the market open.

• EluPro targets this white space, offering a biologic alternative that appeals to competitors and physicians.

Product differentiation and physician feedback

• EluPro uses a natural biologic matrix to down-regulate inflammation, prevent migration, and reduce fibrosis.

• Incorporates an extended-release antibiotic to protect against infection.

• Biologic material remodels into the patient’s own tissue, eliminating long-term foreign body response.

• 88% of polled electrophysiologists using TYRX would consider switching to EluPro.